Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...
Sterling Investment Advisors Ltd. increased its holdings in Regeneron Pharmaceuticals by 23.5% during Q4. The firm now owns 3 ...
In a much-anticipated decision, the First Circuit unanimously ruled the government and relators must prove that a violation ...
The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...
Intellia expects to present longer-term data from the ongoing Phase 1/2 study in 2025. The data will include patients in the ...
The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...
A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...